Evia Bio, Inc. — SEC Form D Filing
Evia Bio, Inc. filed an SEC Form D on September 28, 2026, reporting $5.45M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 28, 2026
- Amount reported
- $5.45M
- Round stage
- Series A, as a $5.4 million raise is the typical size for an early-stage biotechnology company transitioning from laboratory formulation to commercial scaling and clinical validation.
- Industry
- Biotechnology
- Website
- https://eviabio.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Conventional cryopreservation methods for cell and gene therapies rely on toxic agents like dimethyl sulfoxide that damage cells, reduce therapeutic efficacy, and cause adverse patient reactions.
Solution
Evia Bio develops safe, non-toxic, and DMSO-free cryopreservation formulations and technologies to preserve cell and gene therapies without compromising cell viability or patient safety.
Why now
The rapid commercialization and clinical scaling of cell and gene therapies demand safer, highly reliable, and regulatory-compliant preservation methods that eliminate toxic additives.
Source: SEC EDGAR Form D filing